Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04179305 · ClinicalTrials.gov registry record · NA

Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2

A NA study, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
NA
Development phase
37
Enrollment target

NCT04179305 is a NA study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 37 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04179305, a NA study, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
NA
Development phase
37 participants
Enrollment target

Study Summary

When advanced disease progresses, there comes a time when an oncologists must explain to their patients that they only have months left to live. During these discussions the oncologist attempts to explain to the patient their prognoses and what it means for them going forward. However our prior studies shown that even when patients only have months left to live, most do not understand that their cancer is incurable and that it is late/end-stage. Dying cancer patients who fully understand their prognosis are able to make more informed decisions and are therefore more likely to engage in advanced care planning, and receive care what in consistent with their values and preferences. They are also in a better position to avoid burdensome, non-beneficial care. The investigator developed Oncolo-GIST in order to help increase the number of patients who fully understand their prognosis and its implications. Oncolo-GIST is an intervention aimed at enhancing clinicians' communication with patients by teaching them to relay information both sensitively and using simple terminology. The Oncolo-GIST training will provide instruction in areas such as how to introduce the topic of prognosis (describe scan results as "worse"), how to phrase the prognosis itself ("likely months, not years"), how to explain expected treatment outcomes (e.g., "not expected to be cured by treatment") and how to describe expected treatments impact on quality of life - that is, whether the anticancer treatment is likely to make them feel overall better or worse. The training materials consist of a manual and a set of videos that act out situations described in the manual. The second phase of this study will be a randomized controlled trial. The investigator will recruit (n=50) adults with metastatic GI or lung cancers with scan results that reveal progression (worsened disease) on an initial systemic treatment; that is, patients whose life-expectancy can reliably be estimated to be months, not years. M

Interventions

  • BEHAVIORAL Oncolo-GIST
  • BEHAVIORAL Usual Care Arm

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2020-10-25
Est. Completion 2023-01-19
Phase NA

What the Registry Record Tells You About NCT04179305

The ClinicalTrials.gov registry entry for NCT04179305 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Oncolo-GIST is the first listed.

NCT04179305 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04179305 about?

NCT04179305 is a clinical study titled "Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2". When advanced disease progresses, there comes a time when an oncologists must explain to their patients that they only have months left to live. During these discussions the oncologist attempts to explain to the patient their prognoses and what it means for them going forward. However our prior stud...

What is the current status of trial NCT04179305?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2020-10-25. Estimated completion is 2023-01-19.

What interventions are being tested in trial NCT04179305?

The interventions under investigation include: Oncolo-GIST (BEHAVIORAL), Usual Care Arm (BEHAVIORAL).

Who is sponsoring clinical trial NCT04179305?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.